On the 2nd, Huons reported a consolidated revenue of 145.8 billion won and an operating profit of 12.8 billion won for the first quarter of this year. Revenue decreased by 1% compared to the same period last year, while operating profit increased by 20%. The net profit rose by 26% to 12.4 billion won.
Prescription drugs and diabetes medical devices contributed to the performance. At the beginning of the year, flu outbreaks increased antibiotic prescriptions, and sales of chronic disease medications also rose. The company exported injectable drugs worth 4.2 billion won to the United States and exported eye drops to Saudi Arabia and Jordan. The contract manufacturing business and the beauty-wellness business generated revenues of 19.1 billion won and 43.7 billion won, respectively.
Huons' health functional food subsidiary, Huons Pudians, turned a profit in the first quarter of this year. Huons Life Sciences, which manufactures and sells prescription drugs, reduced its losses. Huons expects revenues to increase this year as it expands its injection line in the second half of the year. Huons CEO Song Su-young noted, "We will continue to invest steadily in research and development to secure growth engines."